Idorsia announces financial results for 2020
Idorsia presented
at the 39th J.P. Morgan
Healthcare Conference
Positive results in second
pivotal study with
daridorexant for
patients with
insomnia
Our key assets have
the potential to
transform treatment in
the target indications...
Idorsia today
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.
Idorsia People
Idorsia’s success depends on its people.
Target diseases
Idorsia's development compounds target a number of different diseases.
News
| 04 Feb 2021 | |
| 02 Feb 2021 | |
| 11 Jan 2021 |
Events
| Event | When |
| First Quarter 2021 Financial Results reporting* | April 22, 2021 |
| Annual General Meeting of Shareholders | May 12, 2021 |
| Half-Year 2021 Financial Results reporting* | July 27, 2021 |
| Nine-months 2021 Financial Results reporting* |
October 26, 2021
|
*We will be in a silent period for 10 days ahead of the financial reporting.
Shareprice
Contact
Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil
Switzerland
- +41 58 844 00 00
- Contact us online
- How to get to us